Objective: To explore the effects of cyclophosphamide combined with vinorelbine in advanced small cell lung cancer (SCLC) and anteroposterior changes in MRI.
Methods: The clinical data of 90 patients with advanced SCLC admitted to our hospital from April 2020 to April 2021 were retrospectively analyzed. They were divided into the control group and the study group according to the order of admission, with 45 cases in each group. The control group received the routine treatment, while the study group was treated with cyclophosphamide and vinorelbine to compare the indexes of imaging data and clinical indicators between the two groups before and after treatment.
Results: There was no significant difference in the indexes of imaging data between the two groups before treatment (P > 0.05), and the indexes of imaging data in the study group were visibly lower than those in the control group after treatment (P < 0.001). The DCR in the study group was significantly higher than that in the control group after treatment (P < 0.05), while the QLQ-C30 scores and serum indices of the study group after treatment were significantly lower than those of the control group (P < 0.001).
Conclusion: Patients with advanced SCLC were treated with cyclophosphamide and vinorelbine, which can effectively improve the quality of life and reduce the expression of inflammatory factors. This treatment model has a higher application value, and the treatment value is also reflected compared with the routine treatment. At the same time, the permeability parameters obtained by MRI can predict the therapeutic effects of cyclophosphamide and vinorelbine, and further studies are helpful to establish a better solution for patients.
Copyright © 2022 Zhichun Li and Liliang Ren.